In a breakthrough that could redefine cancer treatment, Russia’s Enteromix vaccine has achieved 100% efficacy and safety in clinical trials. Developed by the Federal Medical and Biological Agency (FMBA), the mRNA-based vaccine trains the immune system to recognize and destroy cancer cells, offering a personalized, side-effect-free alternative to traditional therapies like chemotherapy and radiation.
Announcing the results, FMBA head Veronica Skvortsova said the vaccine demonstrated remarkable tumor-shrinking effects and slowed cancer growth across trial participants. Unlike conventional treatments, Enteromix was well tolerated and safe for repeated use. The vaccine will be customized to each patient’s RNA, allowing highly targeted treatment. Its first application is set to tackle colorectal cancer, with versions for glioblastoma (a lethal brain cancer) and melanoma (a form of skin cancer) already under development.
Enteromix was built using technology similar to COVID-19 vaccines but adapted to oncology. Clinical trials began with 48 volunteers under the Ministry of Health’s National Medical Research Radiology Centre, in collaboration with the Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences. Results presented at the St. Petersburg International Economic Forum 2025 confirmed its potential, highlighting its ability to completely eradicate tumors in some cases.
Unlike existing immunotherapies, Enteromix uses four harmless viruses to attack tumors and stimulate a stronger immune response. Years of testing suggest the vaccine could become the first personalized mRNA cancer vaccine available to the public, once regulatory approval from Russia’s Ministry of Health is granted.
If cleared, Enteromix could revolutionize cancer care, shifting the focus from broad, aggressive treatments to precision-based, patient-specific therapies. For millions worldwide, it represents not just a medical innovation, but a new hope in the fight against one of humanity’s deadliest diseases.
